Stock Analiz

Incannex Healthcare Inc. IXHL

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.97Market cap $25M
Open the interactive analysis →

Incannex Healthcare Inc. (IXHL) is a healthcare company listed in the US with a market value of about $25M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -149%.

About Incannex Healthcare

Incannex Healthcare is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $604884 in 2020 to $86000 in 2025, a decline of about 32.3% a year. It was profitable in 0 of the last 7 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-12.9%
Shareholder yield38.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-104200.0%
ROIC (5-yr avg.)-149.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2026202520242023202220212020
Revenue$0$86000$12000——$2M$604884
Net income-$19M-$47M-$18M-$49M-$15M-$11M-$5M
Free cash flow-$13M-$13M-$16M-$11M———
EPS (diluted)$-1.54$-3.74$-1.47$-3.89$-1.19$-0.91$-0.37
Net margin—-54517.4%-153800.0%——-599.3%-776.6%
ROIC-34.1%-174.3%-204.8%-183.8%—-104.8%-98.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $18.12, 820% above the current price; targets range from $17.49 to $18.76; the consensus rating is “none”; expected EPS is $-2.23 for the fiscal year ending June 30, 2027.

Frequently asked questions

Does Incannex Healthcare pay a dividend?

Not currently.

Is Incannex Healthcare a good stock to buy?

We do not give buy or sell advice. Incannex Healthcare scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.